Ed Hill, Ms, Pmp
About Ed Hill, Ms, Pmp
Ed Hill is the Director of Drug Development Project Management at Bristol Myers Squibb, with over 20 years of experience in pharmaceutical research and development.
Company
Ed Hill currently works at Bristol Myers Squibb as the Director of Drug Development Project Management in Lawrenceville, New Jersey. His role involves providing operational leadership on programs and products aimed at improving human health.
Title
Ed Hill holds the position of Director, Drug Development Project Management. In this role, he is responsible for planning and executing complex, cross-functional global drug and biologic programs from late discovery through lifecycle management.
Previous Work Experience
Ed Hill has accumulated extensive experience in the pharmaceutical industry. Notably, he worked at Johnson & Johnson as the Development Support Leader for the Lung Cancer Initiative from 2020 to 2021. Prior to that, he spent seven years at Janssen, a Pharmaceutical Companies of Johnson & Johnson, where he held multiple leadership roles, including Project Management Leader and Associate Director, Regulatory Program Manager. Earlier in his career, he worked at Merck, starting as an Associate Manager, Regulatory Coordination, and advancing to roles like Clinical and Regulatory Analyst and Associate Project Manager.
Education and Expertise
Ed Hill's academic background includes an MBA in Pharmaceutical Marketing and Management from Saint Joseph's University and a Master's degree in Quality Assurance/Regulatory Affairs from Temple University. He also earned a B.S. in Marketing from Saint Joseph's University. With over 20 years of industry experience in pharmaceutical research and development, he has broad therapeutic area exposure, including oncology, immunology, infectious disease, cardiovascular/metabolism, and neuroscience.
Achievements
Ed Hill is recognized for his effective communication, emotional intelligence, and influencing skills within matrixed teams and across all organizational levels. His proven track record in the industry demonstrates his ability to guide complex drug and biologic programs through various stages, from late discovery to lifecycle management.